Cell line · CVCL_0255
Papers45
1 to 20 of 45
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Plasma Membrane Lipid Asymmetry Dynamically Regulates Passive Diffusion. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Actin conformation dynamics precede force generation in cytotoxic T lymphocytes. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intratumoral Virus-Like Particles Containing a TLR9 Agonist Combined with Systemic αPD-1 Activate Tumor-Specific CD8+ T Cells. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selective Targeting of Tip Endothelial Cells as a Therapeutic Strategy for Tumor Angiogenesis. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PD-1 suppresses CAR signaling by forming the inhibitory signalosome colocalizing to CAR microclusters. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early Detection of Cell Death Using Transmembrane Water Exchange Magnetic Resonance Imaging. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combined Photothermal and mTOR-Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression. | Mol Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responses. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| T cell cholesterol transport links intestinal immune responses to dietary lipid absorption. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Transcriptional adaptation after deletion of Cdc42 in primary T cells. | J Cell Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial complex IV remodeling in tumor-associated macrophages amplifies interferon signaling and promotes anti-tumor immunity. | Immunity | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The TWEAK/Fn14 signaling mediates skeletal muscle wasting during cancer cachexia. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0255/papers